Advanced search

Vol 28 (2024): Continuous Publishing
Guidelines / Expert consensus
Published online: 2024-11-26

open access

View PDF Download PDF file
Page views 79
Article views/downloads 45
Get Citation

Connect on Social Media

Connect on Social Media

Physician–patient partnership — can it help increase adherence to the therapeutic recommendations in cardiovascular disease?

Piotr Dobrowolski1, Aleksander Prejbisz1, Anna Szyndler2, Agnieszka Olszanecka3, Agnieszka Kapłon-Cieślicka4, Marcin Wełnicki5, Piotr Jankowski6, Krzysztof Narkiewicz2, Jacek Wolf2
DOI: 10.5603/ah.103488
Arterial Hypertension 2024;28:50-70.

Abstract

Position statement of the Polish Society of Hypertension and Working Group on Cardiovascular Pharmacotherapy, Polish Cardiac Society endorsed by patient advocacy groups (1) We Patients Foundation, (2) The Institute for Patients’ Rights and Health Education, (3) The National Association of Patients with Heart and Vascular Conditions “EcoHeart/EcoSerce”

 

Efforts to increase adherence to the therapeutic recommendations in primary and secondary prevention of cardiovascular disease include focuses on the improvement of communication between patients and physicians. Physicians need to promote patients’ education and combat disinformation available on the Internet. Use of the electronic methods (e.g., SMS reminders/prompts), elimination of economic barriers, and monitoring of adherence may be also of help. With relation to pharmacotherapy, simplification of drug regimens with wide use single-pill combinations (SPCs) may provide effective measure to substantially improve adherence. Only comprehensive efforts to improve adherence by building a partner patient-physician relationship, may contribute to an increase in persistence and lead to reduction of cardiovascular morbidity and mortality in the general population.

Keywords: drug adherencepharmacotherapypartnershipintegrated caremobile technologiestelemedicinepatient-centered caresingle-pill combinations (SPC)

Article available in PDF format

View PDF Download PDF file

References

  1. Laufs U, Rettig-Ewen V, Böhm M. Strategies to improve drug adherence. Eur Heart J. 2011; 32(3): 264–268.
    CrossRefPubMed
  2. Institut Sapiens (2023), Améliorer l’adhésion thérapeutique: un enjeu de santé publique. https://www.institutsapiens.fr/wp-content/uploads/2023/06/Ameliorer-ladhesion-therapeutique-V1.pdf..
  3. Seaman K, Sanfilippo F, Bulsara M, et al. Increased risk of 2-year death in patients who discontinued their use of statins. J Health Serv Res Policy. 2021; 26(2): 95–105.
    CrossRefPubMed
  4. Kim CL, Do YS, Kim BJ, et al. Clinical impact of medication adherence on 10-year cardio-cerebrovascular mortality in newly diagnosed hypertensive patients. J Clin Hypertens (Greenwich). 2021; 23(9): 1695–1702.
    CrossRefPubMed
  5. Lee H, Yano Y, Cho SoM, et al. Adherence to Antihypertensive Medication and Incident Cardiovascular Events in Young Adults With Hypertension. Hypertension. 2021; 77(4): 1341–1349.
    CrossRefPubMed
  6. Nielsen SF, Nordestgaard BG. Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. Eur Heart J. 2016; 37(11): 908–916.
    CrossRefPubMed
  7. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023; 41(12): 1874–2071.
    CrossRefPubMed
  8. Vrijens B, De Geest S, Hughes DA, et al. ABC Project Team. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012; 73(5): 691–705.
    CrossRefPubMed
  9. Aronson JK. Time to abandon the term ‘patient concordance’. Br J Clin Pharmacol. 2007; 64(5): 711–713.
    CrossRef
  10. WHO. Adherence to long-term therapies: evidence for action. World Health Organization, Geneva, 9241545992, 2003 2003. https://iris.who.int/handle/10665/42682.
  11. R. Horne et al. Concordance, adherence and compliance in medicine taking. Report for the National Co-ordinating Centre for NHS Service Delivery and Organisation R & D (NCCSDO). 2005. https://www.ahpo.net/assets/NCCSDO%20Compliance%202005.pdf.
  12. Elwyn G, Frosch D, Thomson R, et al. Shared decision making: a model for clinical practice. J Gen Intern Med. 2012; 27(10): 1361–1367.
    CrossRefPubMed
  13. Meddings J, Kerr EA, Heisler M, et al. Physician assessments of medication adherence and decisions to intensify medications for patients with uncontrolled blood pressure: still no better than a coin toss. BMC Health Serv Res. 2012; 12: 270.
    CrossRefPubMed
  14. NFZ o zdrowiu. Nadciśnienie tętnicze. Warszawa 2019. https://www.nfz.gov.pl/download/gfx/nfz/pl/defaultstronaopisowa/349/44/1/nadcisnienie-tetnicze-raport-nfz-2019-small.pdf.
  15. Mackenzie IS, Hawkey CJ, Ford I, et al. ALL-HEART Study Group. Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022; 400(10359): 1195–1205.
    CrossRefPubMed
  16. Eskås PA, Heimark S, Eek Mariampillai J, et al. Adherence to medication and drug monitoring in apparent treatment-resistant hypertension. Blood Press. 2016; 25(4): 199–205.
    CrossRefPubMed
  17. Garfield S, Clifford S, Eliasson L, et al. Suitability of measures of self-reported medication adherence for routine clinical use: a systematic review. BMC Med Res Methodol. 2011; 11: 149.
    CrossRefPubMed
  18. Cramer JA. How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989; 261(22): 3273–3277.
    CrossRefPubMed
  19. Burnier M, Schneider MP, Chioléro A, et al. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens. 2001; 19(2): 335–341.
    CrossRefPubMed
  20. Fadl Elmula FE, Hoffmann P, Fossum E, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure. Hypertension. 2013; 62(3): 526–532.
    CrossRefPubMed
  21. Bunker J, Chang CL, Chapman N, et al. True Resistant Hypertension Following Observed Drug Ingestion: A Systematic Evaluation. J Clin Hypertens (Greenwich). 2017; 19(3): 250–255.
    CrossRefPubMed
  22. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009; 119(23): 3028–3035.
    CrossRefPubMed
  23. Robberechts T, Stoenoiu MS, Burnier M, et al. Optimizing drug adherence in hypertension: More than a mind game. Kardiol Pol. 2024; 82(3): 259–266.
    CrossRefPubMed
  24. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006; 333(7557): 15.
    CrossRefPubMed
  25. Burnier M, Egan BM. Adherence in Hypertension. Circ Res. 2019; 124(7): 1124–1140.
    CrossRefPubMed
  26. Vrijens B, Vincze G, Kristanto P, et al. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008; 336(7653): 1114–1117.
    CrossRefPubMed
  27. Berra E, Azizi M, Capron A, et al. Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently Treatment-Resistant Hypertension. Hypertension. 2016; 68(2): 297–306.
    CrossRefPubMed
  28. Choudhry NK, Kronish IM, Vongpatanasin W, et al. American Heart Association Council on Hypertension; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Medication Adherence and Blood Pressure Control: A Scientific Statement From the American Heart Association. Hypertension. 2022; 79(1): e1–e14.
    CrossRefPubMed
  29. Parati G, Stergiou GS, Bilo G, et al. Working Group on Blood Pressure Monitoring and Cardiovascular Variability of the European Society of Hypertension. Home blood pressure monitoring: methodology, clinical relevance and practical application: a 2021 position paper by the Working Group on Blood Pressure Monitoring and Cardiovascular Variability of the European Society of Hypertension. J Hypertens. 2021; 39(9): 1742–1767.
    CrossRefPubMed
  30. Pathak A, Poulter NR, Kavanagh M, et al. Improving the Management of Hypertension by Tackling Awareness, Adherence, and Clinical Inertia: A Symposium Report. Am J Cardiovasc Drugs. 2022; 22(3): 251–261.
    CrossRefPubMed
  31. Chaudri NA. Adherence to Long-term Therapies Evidence for Action. Ann Saudi Med. 2003; 24(3): 221–222.
    CrossRef
  32. Parati G, Kjeldsen S, Coca A, et al. Adherence to Single-Pill Versus Free-Equivalent Combination Therapy in Hypertension: A Systematic Review and Meta-Analysis. Hypertension. 2021; 77(2): 692–705.
    CrossRefPubMed
  33. Rea F, Savaré L, Franchi M, et al. Adherence to Treatment by Initial Antihypertensive Mono and Combination Therapies. Am J Hypertens. 2021; 34(10): 1083–1091.
    CrossRefPubMed
  34. Shi Lu, Zhang D, Wang L, et al. Meditation and blood pressure: a meta-analysis of randomized clinical trials. J Hypertens. 2017; 35(4): 696–706.
    CrossRefPubMed
  35. Schneider MP, Burnier M. Partnership between patients and interprofessional healthcare providers along the multifaceted journey to medication adherence. Br J Clin Pharmacol. 2023; 89(7): 1992–1995.
    CrossRefPubMed
  36. Khan NA, Stergiou GS, Omboni S, et al. Virtual management of hypertension: lessons from the COVID-19 pandemic-International Society of Hypertension position paper endorsed by the World Hypertension League and European Society of Hypertension. J Hypertens. 2022; 40(8): 1435–1448.
    CrossRefPubMed
  37. De Geest S, Sabaté E. Adherence to long-term therapies: evidence for action. Eur J Cardiovasc Nurs. 2003; 2(4): 323.
    CrossRefPubMed
  38. McGuire LC. Remembering what the doctor said: organization and adults' memory for medical information. Exp Aging Res. 1996; 22(4): 403–428.
    CrossRefPubMed
  39. Naughton CA. Patient-Centered Communication. Pharmacy (Basel). 2018; 6(1).
    CrossRefPubMed
  40. Ryan R, Santesso N, Lowe D, et al. Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews. Cochrane Database Syst Rev. 2014; 2014(4): CD007768.
    CrossRefPubMed
  41. Glynn LG, Murphy AW, Smith SM, et al. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev. 2010(3): CD005182.
    CrossRefPubMed
  42. Anderson L, Brown JPr, Clark AM, et al. Patient education in the management of coronary heart disease. Cochrane Database Syst Rev. 2017; 6(6): CD008895.
    CrossRefPubMed
  43. Clyne W, McLachlan S, Mshelia C, et al. "My patients are better than yours": optimistic bias about patients' medication adherence by European health care professionals. Patient Prefer Adherence. 2016; 10: 1937–1944.
    CrossRefPubMed
  44. Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev. 2004; 2004(2): CD004804.
    CrossRefPubMed
  45. Mulder-Vos I, Driever EM, Brand PLP. Observational study on the timing and method of interruption by hospital consultants during the opening statement in outpatient consultations. BMJ Open. 2023; 13(9): e066678.
    CrossRefPubMed
  46. Miller W, Rollnick S. Motivational interviewing: Helping people change. Guilford Press, New York, London 2012.
  47. Sacristán JA. Patient-centered medicine and patient-oriented research: improving health outcomes for individual patients. BMC Med Inform Decis Mak. 2013; 13: 6.
    CrossRefPubMed
  48. Somani S, van Buchem MM, Sarraju A, et al. Artificial Intelligence-Enabled Analysis of Statin-Related Topics and Sentiments on Social Media. JAMA Netw Open. 2023; 6(4): e239747.
    CrossRefPubMed
  49. Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376(9753): 1670–1681.
    CrossRefPubMed
  50. Fröbert O, Götberg M, Erlinge D, et al. Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Circulation. 2021; 144(18): 1476–1484.
    CrossRefPubMed
  51. Slavin SD, Berman AN, Gaba P, et al. Influenza vaccination and use of lipid lowering therapies in adults with atherosclerotic cardiovascular disease: An analysis of the Behavioral Risk Factor Surveillance System (BRFSS). Am Heart J. 2024; 268: 1–8.
    CrossRefPubMed
  52. Cholesterol Treatment Trialists' Collaboration. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet. 2022; 400(10355): 832–845.
    CrossRefPubMed
  53. Wood FA, Howard JP, Finegold JA, et al. N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects. N Engl J Med. 2020; 383(22): 2182–2184.
    CrossRefPubMed
  54. Bogle BM, Ning H, Mehrotra S, et al. Lifetime Risk for Sudden Cardiac Death in the Community. J Am Heart Assoc. 2016; 5(7).
    CrossRefPubMed
  55. Qvarnström M, Kahan T, Kieler H, et al. Persistence to antihypertensive drug treatment in Swedish primary healthcare. Eur J Clin Pharmacol. 2013; 69(11): 1955–1964.
    CrossRefPubMed
  56. Hughes CM. Medication non-adherence in the elderly: how big is the problem? Drugs Aging. 2004; 21(12): 793–811.
    CrossRefPubMed
  57. Elliott RA, Goeman D, Beanland C, et al. Ability of older people with dementia or cognitive impairment to manage medicine regimens: a narrative review. Curr Clin Pharmacol. 2015; 10(3): 213–221.
    CrossRefPubMed
  58. Smith D, Lovell J, Weller C, et al. A systematic review of medication non-adherence in persons with dementia or cognitive impairment. PLoS One. 2017; 12(2): e0170651.
    CrossRefPubMed
  59. Scuteri A, Spazzafumo L, Cipriani L, et al. Depression, hypertension, and comorbidity: disentangling their specific effect on disability and cognitive impairment in older subjects. Arch Gerontol Geriatr. 2011; 52(3): 253–257.
    CrossRefPubMed
  60. Moise N, Davidson KW, Chaplin W, et al. Depression and clinical inertia in patients with uncontrolled hypertension. JAMA Intern Med. 2014; 174(5): 818–819.
    CrossRefPubMed
  61. Madden JM, Graves AJ, Zhang F, et al. Cost-related medication nonadherence and spending on basic needs following implementation of Medicare Part D. JAMA. 2008; 299(16): 1922–1928.
    CrossRefPubMed
  62. Visco V, Finelli R, Pascale AV, et al. Difficult-to-control hypertension: identification of clinical predictors and use of ICT-based integrated care to facilitate blood pressure control. J Hum Hypertens. 2018; 32(7): 467–476.
    CrossRefPubMed
  63. Burnier M, Polychronopoulou E, Wuerzner G. Hypertension and Drug Adherence in the Elderly. Front Cardiovasc Med. 2020; 7: 49.
    CrossRefPubMed
  64. Pagès-Puigdemont N, Tuneu L, Masip M, et al. Determinants of medication adherence among chronic patients from an urban area: a cross-sectional study. Eur J Public Health. 2019; 29(3): 419–424.
    CrossRefPubMed
  65. Bandi P, Goldmann E, Parikh NS, et al. Age-Related Differences in Antihypertensive Medication Adherence in Hispanics: A Cross-Sectional Community-Based Survey in New York City, 2011-2012. Prev Chronic Dis. 2017; 14: E57.
    CrossRefPubMed
  66. Weingarten MA, Cannon BS. Age as a major factor affecting adherence to medication for hypertension in a general practice population. Fam Pract. 1988; 5(4): 294–296.
    CrossRefPubMed
  67. Kostev K, Yakkali B, Chaudhari S, et al. Persistence with first-line antihypertensive therapy in Germany: A retrospective cohort study with 2,801,469 patients. Int J Clin Pharmacol Therapeut. 2023; 61(05): 189–195.
    CrossRef
  68. Ge L, Heng BH, Yap CW. Understanding reasons and determinants of medication non-adherence in community-dwelling adults: a cross-sectional study comparing young and older age groups. BMC Health Serv Res. 2023; 23(1): 905.
    CrossRefPubMed
  69. Tajeu GS, Kent ST, Kronish IM, et al. Trends in Antihypertensive Medication Discontinuation and Low Adherence Among Medicare Beneficiaries Initiating Treatment From 2007 to 2012. Hypertension. 2016; 68(3): 565–575.
    CrossRefPubMed
  70. Friedman O, McAlister FA, Yun L, et al. Canadian Hypertension Education Program Outcomes Research Taskforce. Antihypertensive drug persistence and compliance among newly treated elderly hypertensives in ontario. Am J Med. 2010; 123(2): 173–181.
    CrossRefPubMed
  71. Yang Q, Chang A, Ritchey MD, et al. Antihypertensive Medication Adherence and Risk of Cardiovascular Disease Among Older Adults: A Population-Based Cohort Study. J Am Heart Assoc. 2017; 6(6).
    CrossRefPubMed
  72. Consolazio D, Gattoni ME, Russo AG. Exploring gender differences in medication consumption and mortality in a cohort of hypertensive patients in Northern Italy. BMC Public Health. 2022; 22(1): 768.
    CrossRefPubMed
  73. Rea F, Mella M, Monzio Compagnoni M, et al. Women discontinue antihypertensive drug therapy more than men. Evidence from an Italian population-based study. J Hypertens. 2020; 38(1): 142–149.
    CrossRefPubMed
  74. Erkens JA, Panneman MMJ, Klungel OH, et al. Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf. 2005; 14(11): 795–803.
    CrossRefPubMed
  75. Kulkarni S, Rao R, Goodman JD, et al. Nonadherence to antihypertensive medications amongst patients with uncontrolled hypertension: A retrospective study. Medicine (Baltimore). 2021; 100(14): e24654.
    CrossRefPubMed
  76. Biffi A, Rea F, Iannaccone T, et al. Sex differences in the adherence of antihypertensive drugs: a systematic review with meta-analyses. BMJ Open. 2020; 10(7): e036418.
    CrossRefPubMed
  77. Polaczyk M, Olszanecka A, Wojciechowska W, et al. Multiple drug intolerance in patients with arterial hypertension: prevalence and determining factors. Pol Arch Intern Med. 2023; 133(3).
    CrossRefPubMed
  78. Osude N, Durazo-Arvizu R, Markossian T, et al. Age and sex disparities in hypertension control: The multi-ethnic study of atherosclerosis (MESA). Am J Prev Cardiol. 2021; 8: 100230.
    CrossRefPubMed
  79. Gu Q, Burt VL, Paulose-Ram R, et al. Gender differences in hypertension treatment, drug utilization patterns, and blood pressure control among US adults with hypertension: data from the National Health and Nutrition Examination Survey 1999-2004. Am J Hypertens. 2008; 21(7): 789–798.
    CrossRefPubMed
  80. Marx N, Federici M, Schütt K, et al. ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023; 44(39): 4043–4140.
    CrossRefPubMed
  81. Tykarski A, Filipiak K, Januszewicz A, et al. 2019 Guidelines for the Management of Hypertension — Part 1–7. Arterial Hypertens. 2019; 23(2): 41–87.
    CrossRef
  82. Szymański F, Mickiewicz A, Dzida G, et al. Leczenie dyslipidemii w Polsce — interdyscyplinarne stanowisko grupy ekspertów wsparte przez Sekcję Farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. IV Deklaracja Sopocka. Choroby Serca i Naczyń. 2021; 18(3): 95–120.
    CrossRef
  83. Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med. 2012; 125(9): 882–887.e1.
    CrossRefPubMed
  84. Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013; 34(38): 2940–2948.
    CrossRefPubMed
  85. Castellano JM, Sanz G, Peñalvo JL, et al. A polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol. 2014; 64(20): 2071–2082.
    CrossRefPubMed
  86. Choudhry NK, Glynn RJ, Avorn J, et al. Untangling the relationship between medication adherence and post-myocardial infarction outcomes: medication adherence and clinical outcomes. Am Heart J. 2014; 167(1): 51–58.e5.
    CrossRefPubMed
  87. Simons LA, Chung E, Ortiz M. Long-term persistence with single-pill, fixed-dose combination therapy versus two pills of amlodipine and perindopril for hypertension: Australian experience. Curr Med Res Opin. 2017; 33(10): 1783–1787.
    CrossRefPubMed
  88. Weisser B, Predel HG, Gillessen A, et al. Single Pill Regimen Leads to Better Adherence and Clinical Outcome in Daily Practice in Patients Suffering from Hypertension and/or Dyslipidemia: Results of a Meta-Analysis. High Blood Press Cardiovasc Prev. 2020; 27(2): 157–164.
    CrossRefPubMed
  89. Castellano JM, Pocock SJ, Bhatt DL, et al. SECURE Investigators. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med. 2022; 387(11): 967–977.
    CrossRefPubMed
  90. Snyman JR, Bortolotto LA, Degli Esposti L, et al. A real-world analysis of outcomes and healthcare costs of patients on perindopril/indapamide/amlodipine single-pill vs. multiple-pill combination in Italy. J Hypertens. 2024; 42(1): 136–142.
    CrossRefPubMed
  91. Rea F, Morabito G, Savaré L, et al. Adherence and related cardiovascular outcomes to single pill vs. separate pill administration of antihypertensive triple-combination therapy. J Hypertens. 2023; 41(9): 1466–1473.
    CrossRefPubMed
  92. Van Wilder L, Devleesschauwer B, Clays E, et al. Polypharmacy and Health-Related Quality of Life/Psychological Distress Among Patients With Chronic Disease. Prev Chronic Dis. 2022; 19: E50.
    CrossRefPubMed
  93. Chaudhry UAR, Wahlich C, Fortescue R, et al. The effects of step-count monitoring interventions on physical activity: systematic review and meta-analysis of community-based randomised controlled trials in adults. Int J Behav Nutr Phys Act. 2020; 17(1): 129.
    CrossRefPubMed
  94. Qiu S, Cai X, Ju C, et al. Step Counter Use and Sedentary Time in Adults: A Meta-Analysis. Medicine (Baltimore). 2015; 94(35): e1412.
    CrossRefPubMed
  95. Kaihara T, Intan-Goey V, Scherrenberg M, et al. Automatic transmission of home blood pressure data can be effective in managing hypertension: a systematic review and meta-analysis. Eur Heart J Digit Health. 2022; 3(4): 638–653.
    CrossRefPubMed
  96. De Groot J, Wu D, Flynn D, et al. Efficacy of telemedicine on glycaemic control in patients with type 2 diabetes: A meta-analysis. World J Diabetes. 2021; 12(2): 170–197.
    CrossRefPubMed
  97. Turan Kavradim S, Özer Z, Boz İ. Effectiveness of telehealth interventions as a part of secondary prevention in coronary artery disease: a systematic review and meta-analysis. Scand J Caring Sci. 2020; 34(3): 585–603.
    CrossRefPubMed
  98. Inglis SC, Clark RA, Dierckx R, et al. Structured telephone support or non-invasive telemonitoring for patients with heart failure. Cochrane Database Syst Rev. 2015; 2015(10): CD007228.
    CrossRefPubMed
  99. Chauhan U, McAlister FA. Comparison of Mortality and Hospital Readmissions Among Patients Receiving Virtual Ward Transitional Care vs Usual Postdischarge Care: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022; 5(6): e2219113.
    CrossRefPubMed
  100. Flodgren G, Rachas A, Farmer AJ, et al. Interactive telemedicine: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2015; 2015(9): CD002098.
    CrossRefPubMed
  101. Bingham JM, Black M, Anderson EJ, et al. Impact of Telehealth Interventions on Medication Adherence for Patients With Type 2 Diabetes, Hypertension, and/or Dyslipidemia: A Systematic Review. Ann Pharmacother. 2021; 55(5): 637–649.
    CrossRefPubMed
  102. Izeogu C, Kalinowski J, Schoenthaler A. Strategies to Improve Adherence to Anti-Hypertensive Medications: a Narrative Review. Curr Hypertens Rep. 2020; 22(12): 105.
    CrossRefPubMed
  103. Peacock E, Craig LS, Krousel-Wood M. Electronic health strategies to improve medication adherence in patients with cardiometabolic disease: current status and future directions. Curr Opin Cardiol. 2022; 37(4): 307–316.
    CrossRefPubMed
  104. Tam HL, Leung LY, Wong EM, et al. Integration of text messaging interventions into hypertension management among older adults: A systematic review and meta-analysis. Worldviews Evid Based Nurs. 2022; 19(1): 16–27.
    CrossRefPubMed
  105. Sartori AC, Rodrigues Lucena TF, Lopes CT, et al. Educational Intervention Using on Medication Adherence in Hypertension and Diabetes Patients: A Randomized Clinical Trial. Telemed J E Health. 2020; 26(12): 1526–1532.
    CrossRefPubMed
  106. Roca S, Lozano ML, García J, et al. Validation of a Virtual Assistant for Improving Medication Adherence in Patients with Comorbid Type 2 Diabetes Mellitus and Depressive Disorder. Int J Environ Res Public Health. 2021; 18(22).
    CrossRefPubMed
  107. He Q, Zhao X, Wang Y, et al. Effectiveness of smartphone application-based self-management interventions in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. J Adv Nurs. 2022; 78(2): 348–362.
    CrossRefPubMed
  108. Xu H, Long H. The Effect of Smartphone App-Based Interventions for Patients With Hypertension: Systematic Review and Meta-Analysis. JMIR Mhealth Uhealth. 2020; 8(10): e21759.
    CrossRefPubMed
  109. Mikulski BS, Bellei EA, Biduski D, et al. Mobile Health Applications and Medication Adherence of Patients With Hypertension: A Systematic Review and Meta-Analysis. Am J Prev Med. 2022; 62(4): 626–634.
    CrossRefPubMed
  110. Munshi KD, Amelung K, Carter CS, et al. Impact of a diabetes remote monitoring program on medication adherence. J Manag Care Spec Pharm. 2021; 27(6): 724–731.
    CrossRefPubMed
  111. Meng WW, Bai YYi, Yan Li, et al. Effect of Home Blood Pressure Telemonitoring Plus Additional Support on Blood Pressure Control: A Randomized Clinical Trial. Biomed Environ Sci. 2023; 36(6): 517–526.
    CrossRefPubMed
  112. NHS. Shared decision-making. https://www.england.nhs.uk/personalisedcare/shared-decision-making/ (August 12, 2024).

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2024 Via Medica Regulations Cookie policy Privacy Statement Legal Note